Clinical trial · Interventional
Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura
A Phase II Study of Pleural Photodynamic Therapy for Patients With Non-small Cell Lung Cancer and Pleural Spread
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor accrual and change in standards of care
Summary
Brief summary (as posted)
RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that is absorbed by tumor cells. The drug becomes active when it is exposed to light. When the drug is active, tumor cells are killed. Giving photodynamic therapy during surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying the side effects and how well photodynamic therapy given during surgery works in treating patients with resectable non-small cell lung cancer that has spread to the pleura.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemotherapy | Drug | Chemotherapy | ALIAS |
| immunohistochemistry staining method | Other | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| porfimer sodium | Drug | Porfimer | ALIAS |
| spectroscopy | Procedure | — | UNRESOLVED |
| therapeutic conventional surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Photodynamic Therapy
- description
- PDT
- interventionNames
- Drug: chemotherapy
- Drug: porfimer sodium
- Other: immunohistochemistry staining method
- Other: laboratory biomarker analysis
- Procedure: spectroscopy
- Procedure: therapeutic conventional surgery
Primary outcomes (3)
- measure
- Toxicity Assessment of Pleural Photodynamic Therapy
- timeFrame
- One year
- description
- Toxicities of PDT as defined by CTCAE v4.0
- measure
- Overall Survival
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed non-small cell lung cancer (NSCLC) * Must have clinical and/or pathological evidence of pleural spread * Primary tumor must be resectable as assessed by the attending thoracic surgeon * Patients who have received or are currently receiving two-to-four courses of standard front-line chemotherapy are eligible PATIENT CHARACTERISTICS: * Must be medically fit to tolerate surgery * No CTCAE v3.0 grade III-IV elevations in liver transaminases * Bilirubin ≤ 1.5 mg/dL * No known HIV infection * Not pregnant or nursing PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior treatment for NSCLC except pleurodesis or standard front-line chemotherapy * No prior pemetrexed disodium chemotherapy * No prior mantle radiotherapy * No concurrent chemotherapy or radiotherapy during the active study treatment period * Post-operative radiotherapy will be administered as clinically indicated
References
Publications (0)
Data not yet available